The ability to arm targeting molecules with beta-emitter, Yttrium-90, creates potent, purely therapeutic agents that are ideal for bigger tumors due to the powerful long-range crossfire effect. Alfa Cytology has the specialized radiochemistry expertise and infrastructure and the ability to stably conjugate Yttrium-90 to multiple targeting vectors to provide high-purity, therapeutic-grade radiopharmaceuticals for impactful preclinical research.
Yttrium-90 (90Y) is a high-energy, pure beta-emitting radionuclide that serves as a powerful workhorse for targeted radionuclide therapy. 90Y delivers a potent, cytotoxic dose via beta particles with a half-life of 64.1 hours. The beta particles have a long range of several millimeters, and thus, the 90Y is able to reach and treat larger and solid tumors. Its marked crossfire effect allows it to kill adjacent, non-targeted cancer cells. 90Y is primarily therapeutic as it possesses no useful gamma emission for imaging, and is most prominently employed in the radioembolization of liver malignancies and radioimmunotherapy.
Therapeutics based on the yttrium-90 isotope, with the name 90Y radiopharmaceuticals, are primarily used for applying targeted therapy for certain kinds of malignancies. 90Y emits energetic beta particles and has a half-life of nearly 2.67 days, providing ideal therapeutic doses in vivo. Precisely targeting cancer markers for tumor-specific therapy is possible through the 90Y radiolabeling of appropriate antibodies, ligands, or other carriers. Probably the greatest benefit of this approach is the protection of normal tissue with a concomitant increase of radiative energy concentration in cancer cells.
Fig. 1 Yttrium-90 ibritumomab tiuxetan. (ALHAJ MOUSTAFA M, et al., 2023)
| Name | Company | Application | Phase |
|---|---|---|---|
| Zevalin® | Acrotech Biopharma LLC | - | Approved FDA |
| Hematology CD66 | Telix Pharmaceuticals | - |
Disclaimer: Alfa Cytology focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Alfa Cytology is focused on creating cutting-edge 90Y radiopharmaceuticals and intends to construct precision oncology therapeutics using targeted molecular technology together with radioisotope yttrium-90. Our 90Y radiopharmaceutical development service, which encompasses the entire range from drug design and synthesis to preclinical evaluation and ensures the therapeutic agents are both effective and safe.
90Y conjugation leverages advanced chelation chemistry to arm novel targeting vectors with Yttrium-90, creating potent radiotherapeutics designed to eradicate large or poorly vascularized tumors through a powerful crossfire effect.
Verification of the successful incorporation of 90Y is necessary after the labeling is done. It is done through a variety of checks; liquid chromatography (LC), mass spectrometry (MS), and scintillation counting are all analytical methods. These all help to quantify the labeling and check the correct isotopic labeling, purity, and composition of the compound to ensure it is fit for biological studies.
In vitro tests are performed to evaluate the biological properties of the 90Y-labeled radiopharmaceutical. This includes studying its interaction with target receptors, cellular uptake, metabolic stability, and other pharmacological properties.
The last part encompasses testing within an organism to examine pharmacokinetics and biodistribution while monitoring the compound's behavior as a whole. Imaging and radiometric techniques enable tracking of the tissue distribution of the 90Y-labeled compound to gain an understanding of its therapeutic potential and safety profile, and tissue targeting.
The applications of 90Y-radiolabeling are centered on the development of potent radiotherapeutics. Yttrium-90's high-energy beta particles are suitable for the radiotherapeutic therapy of large, solid, or poorly vascularized tumor burdens through the powerful crossfire effect.
Systemic Targeted Radionuclide Therapy
Preclinical Research & Development
Dedicated to pioneering cancer therapeutics through advances in medical technology, Alfa Cytology is a top specialist in the development of 90Y radiopharmaceuticals. Enhanced precision oncology therapeutics are incorporated in our range of innovative services, from designing a targeted molecule to conducting detailed preclinical studies. If you would like to learn more about our advanced 90Y radiopharmaceutical development services, do not hesitate to contact us directly.
Reference
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2025 Alfa Cytology. All rights reserved.
